



Bal Pharma Limited

To,
The Manager-Listing
BSE Limited
Mumbai.

23.9.2019

To
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Proceedings of 32nd Annual General Meeting ('AGM') held on 23.9.2019.
Ref : Scrip code 524824 for BSE and BALPH for NSE.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the 32nd Annual General Meeting of the Company held on 23.09.2019, at Bharatiya Vidya Bhavan, Race Course Road, Bangalore-560001.

The Meeting commenced at 10.30 AM and concluded at 12.00 PM.

Ordinary Business:

1. Approved the Audited financial statements of the Company for the financial year ended 31.3.2019, together with Board's report and Independent Auditors Report.
2. Declared a dividend of Re.1/- per equity share of Rs.10/- each (i.e 10%), for the financial year ended 31.3.2019.
3. Reappointed Dr.Subbarao Prasanna, who was retiring by rotation and has offered himself for reappointment.

Special Business:

4. Approved the increase of Authorised Share Capital of the Company from Rs.15.00 Crores to Rs.20.00 Crores.
5. Approved the alteration of Capital clause of Memorandum of Association.
6. Approved the alteration of Capital clause of Articles of Association.

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052, India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820



7. Reappointed Mr. Shailesh D Siroya as Managing Director of the Company for a period of 5 years and approved his remuneration for the next 3 years.
8. Appointed Dr. C.V Srinivas as Director of the Company for a period of 5 years.
9. Appointed Dr. C.V Srinivas as Independent Director of the Company.
10. Reappointed Mr. Pramod Kumar. S as Independent Director of the Company for a period of 5 years.
11. Ratified the remuneration payable to the Cost Auditors.

Kindly note that e-voting and ballot results will be announced after receipt of Scrutinizer's Report and the same will be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited


Shailesh Siroya
Managing Director

